Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents

Xia, Xiaohuan; Wang, Yi; Huang, Yunlong; Zhang, Han; Lü, Hongfang; Zheng, Jialin

doi:10.1016/j.pneurobio.2019.101694

Cited by 134 publications

(136 citation statements)

References 254 publications

Supporting

Mentioning

136

Contrasting

Order By: Relevance

“…EV-carried small RNAs are also proposed as diagnostic biomarkers such as for patients suffering from solitary pulmonary nodules (SPNs), neurodegenerative disease, infectious diseases (i.e. HIV infection) and cancer [66][67][68][69][70]. Others researchers have also proposed long non-coding RNA, EV-associated gDNA or combination of RNA species as biomarkers.…”

Section: Ev Biomarker Detection and Application In Clinical Diagnosismentioning

confidence: 99%

The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

Soekmadji

Huang

et al. 2020

J of Extracellular Vesicle

View full text Add to dashboard Cite

The utilization of extracellular vesicles (EVs) in clinical theranostics has rapidly advanced in the past decade. In November 2018, the International Society for Extracellular Vesicles (ISEV) held a workshop on “EVs in Clinical Theranostic”. Here, we report the conclusions of roundtable discussions on the current advancement in the analysis technologies and we provide some guidelines to researchers in the field to consider the use of EVs in clinical application. The main challenges and the requirements for EV separation and characterization strategies, quality control and clinical investigation were discussed to promote the application of EVs in future clinical studies.

show abstract

Section: Ev Biomarker Detection and Application In Clinical Diagnosismentioning

confidence: 99%

The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

Soekmadji

Huang

et al. 2020

J of Extracellular Vesicle

View full text Add to dashboard Cite

show abstract

“…Thus, multiple synthetic or natural nanocarriers have been applied in miR-17~92 delivery, including aforementioned exosomes. Emerging evidence has implicated exosomes as an excellent natural platform for delivering miRNA into the CNS due to superior miRNAs preservation from the RNases, promising targeting capacity post equipping with homing molecules, ability to penetrate the BBB, low-or non-immunogenicity, and flexibility in administration routes [74][75][76][77][78]. These unparalleled characteristics make exosome-based miRNA delivery an interesting and important direction for the development of novel therapeutic strategies for treating neurological disorders.…”

Section: Mir-17~92 Family As Regenerative "Medicine"mentioning

confidence: 99%

The microRNA-17 ~ 92 Family as a Key Regulator of Neurogenesis and Potential Regenerative Therapeutics of Neurological Disorders

Xia

Wang

Zheng

2020

Stem Cell Rev and Rep

Self Cite

View full text Add to dashboard Cite

miR-17 ~ 92, an miRNA family containing three paralogous polycistronic clusters, was initially considered as an oncogene and was later demonstrated to trigger various physiological and pathological processes. Emerging evidence has implicated miR-17 ~ 92 family as a master regulator of neurogenesis. Through targeting numerous genes that affect cell cycle arrest, stemness deprivation, and lineage commitment, miR-17 ~ 92 family controls the proliferation and neuronal differentiation of neural stem/progenitor cells in both developmental and adult brains. Due to the essential roles of miR-17 ~ 92 family, its misexpression is widely associated with acute and chronic neurological disorders by attenuating neurogenesis and facilitating neuronal apoptosis. The promising neurogenic potential of miR-17 ~ 92 family also makes it a promising “medicine” to activate the endogenous and exogenous regenerative machinery, thus enhance tissue repair and function recovery after brain injury. In this review, we focus on the recent progress made toward understanding the involvement of miR-17 ~ 92 family in regulating both developmental and adult neurogenesis, and discuss the regenerative potential of miR-17 ~ 92 family in treating neurological disorders.

show abstract

“…Several features make exosomal miRNAs useful biomarkers of central nervous system diseases, including AD. These characteristics include: Exosomal miRNAs are easily accessible and exosomes are abundantly present in various biological fluids and can be extracted with relative ease without excessively invasive procedures [ 66 , 94 ]. Indeed, exosomes are able to cross the BBB and, therefore, can be detected through simple venous sampling.…”

Section: Discussionmentioning

confidence: 99%

Exosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer’s Disease

et al. 2020

View full text Add to dashboard Cite

Alzheimer’s disease (AD), a neurodegenerative disease, is linked to a variety of internal and external factors present from the early stages of the disease. There are several risk factors related to the pathogenesis of AD, among these exosomes and microRNAs (miRNAs) are of particular importance. Exosomes are nanocarriers released from many different cell types, including neuronal cells. Through the transfer of bioactive molecules, they play an important role both in the maintenance of physiological and in pathological conditions. Exosomes could be carriers of potential biomarkers useful for the assessment of disease progression and for therapeutic applications. miRNAs are small noncoding endogenous RNA sequences active in the regulation of protein expression, and alteration of miRNA expression can result in a dysregulation of key genes and pathways that contribute to disease development. Indeed, the involvement of exosomal miRNAs has been highlighted in various neurodegenerative diseases, and this opens the possibility that dysregulated exosomal miRNA profiles may influence AD disease. The advances in exosome-related biomarker detection in AD are summarized. Finally, in this review, we highlight the use of exosomal miRNAs as essential biomarkers in preclinical and clinical studies in Alzheimer’s disease, also taking a look at their potential clinical value.

show abstract

Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents

Cited by 134 publications

References 254 publications

The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

The microRNA-17 ~ 92 Family as a Key Regulator of Neurogenesis and Potential Regenerative Therapeutics of Neurological Disorders

Exosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer’s Disease

Contact Info

Product

Resources

About